Tanzeum (albiglutide) Pen, Dosage, Price, Side Effects, Weight Loss, and PI for Type 2 Diabetes | Samar Borhani, PharmD | RxEconsult

All Health Articles

Tanzeum (albiglutide) Pen, Dosage, Price, Side Effects, Weight Loss Category: Diabetes by - May 28, 2014 | Views: 76131 | Likes: 3 | Comment: 0  

Tanzeum Pen

Brand Name: Tanzeum
Generic Name: albiglutide

Drug Class: Glucagon-like peptide-1 (GLP-1) receptor agonist
Similar Drugs: Victoza (liraglutide) Byetta (exenatide) Bydureon (exenatide extended release)
Manufacturer: GlaxoSmithKline
FDA Approval Date: April 15, 2014

What is Tanzeum and its mechanism of action?

Tanzeum is a new injectable diabetes drug approved by FDA in April 2014 for use in adults with type 2 diabetes mellitus. Tanzeum belongs to a group of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists because they resemble and mimic the action of human GLP-1 hormone (incretin hormone). They are also known as incretin mimetics. It is an injectable drug that reduces blood glucose by increasing insulin production by the pancreas, slows the absorption of glucose from the gut, reduces the activity of glucagon (a hormone that increases the release of glucose from the liver), and reduces appetite. 

What does Tanzeum treat?

Tanzeum is combined with diet and exercise to improve glucose control in adults with type 2 diabetes mellitus. 

Who should not use Tanzeum?

  • Tanzeum is not recommended as first-line therapy for patients not controlled
    by diet and exercise alone.
  • Tanzeum is contraindicated in patients with a history of medullary thyroid cancer or Multiple Endocrine Neoplasia Syndrome Type 2 (MEN 2).
  • Patients should be aware of risks and symptoms of thyroid tumors before using Tanzeum.
  • Tanzeum is not indicated to be used in patients with type 1 diabetes mellitus or patients with the history of diabetic ketoacidosis.
  • It is not recommended in patients with severe stomach or intestinal problems.
  • It has not been studied in people with a history of pancreatitis.

How effective is Tanzeum?

Monotherapy: In a 52-week long trial, 296 patients were randomly placed on Tanzeum 30 mg treatment or placebo. By week 52 there was a significant decrease in HbA1C levels from the baseline in patients on 30 mg (-0.7%) or 50 mg (-0.9%) of Tanzeum compared to patients on placebo (+0.2%). There was no significant change in the average body weight from the baseline reported in this study.   

Combination Therapy: During a 104-week long trial, 999 patients with type 2 diabetes mellitus inadequately controlled on metformin therapy were randomly given Tanzeum 30 mg or placebo, sitagliptin 100 mg daily, or glimepiride 2 mg daily. By week 104 there was a significant decrease in HbA1C levels from the baseline in patients on Tanzeum 30 mg plus metformin (-0.6%) compared to placebo plus metformin (+0.3%), sitagliptin plus metformin (-0.3%), or glimepiride plus metformin (-0.4%). There was also a significant change in average body weight from the baseline between Tanzeum (90 kg) and glimepiride (92 kg).

Interesting facts about Tanzeum

  • Tanzeum has also been approved in European countries and will be marketed as Eperzan.
  • Tanzeum may decrease appetite, therefore, cause weight loss in patients.
  • Unlike some other diabetes medications, the dosage of Tanzeum does not need to be adjusted in patients with renal impairment.
  • It is a once a week injection that may increase patient adherence with less risk of injection site reactions.


Next: Dosing, Side Effects, Drug Interactions, Cost


For More Healthcare Insights Join Us On Twitter
and Facebook. Join The Community To Publish Articles.

Copyright 2024 RxEconsult. All Rights Reserved | Privacy Policy | Terms of Use | Sitemap